Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure Drugs' hidden impact on lungs revealed in tiny study

NCT ID NCT07603037

Knowledge-focused Sponsor: First Affiliated Hospital of Wannan Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This small pilot study will test two common blood pressure medicines—nicardipine and sodium nitroprusside—in 12 patients with acute respiratory failure and high blood pressure. Researchers will use a special imaging technique called electrical impedance tomography to see how these drugs change the balance of air and blood flow in the lungs. The goal is to find out which drug is safer and better for these critically ill patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Diagnosis of acute respiratory failure with PaO₂/FiO₂ ≤ 300 mmHg, requiring invasive mechanical ventilation. Requires intravenous antihypertensive infusion (such as nicardipine or nitroglycerin) to maintain controlled and stable blood pressure during ICU treatment. Written informed consent obtained from the patient or the legally authorized representative. Exclusion Criteria: Body mass index (BMI) ≥ 50 kg/m² or presence of massive subcutaneous edema interfering with EIT signal acquisition. Implanted cardiac pacemaker, defibrillator, or any metallic thoracic device that may distort impedance measurements. Hemodynamic instability or severe hypotension occurring during drug titration. Pregnancy or lactation. Known hypersensitivity or contraindication to nicardipine or nitroglycerin. Use of phosphodiesterase-5 inhibitors, such as sildenafil, tadalafil, or vardenafil, within the clinically relevant washout period. Severe anemia, markedly increased intracranial pressure, or other clinical conditions in which nitroglycerin administration is considered inappropriate by the treating physician. Incomplete clinical documentation preventing accurate evaluation of primary endpoints.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory failure Aortic Dissection hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute respiratory failure (ARF) Aortic dissection (subset) Hypertension Pulmonary perfusion imbalance

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)

    Wuhu, Anhui, 241001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.